SH3KBP1 and hepatocellular carcinoma: Sorafenib, a first‐line therapeutic agent for advanced inoperable HCC, was administered either alone or in conjunction with an adeno‐associated virus (AAV) targeting SH3KBP1 in PDX mice (Figure 6E).